ENDRA Life Sciences Inc. (NDRA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. ENDRA Life Sciences Inc. is a biotechnology company developing a thermo-acoustic medical device (TAEUS) for accurate liver fat measurement, targeting metabolic disease detection and GLP-1 drug eligibility management. The company has not yet generated product revenue and remains in the development and pre-commercialization phase.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(1,225,912) | $(2,262,242) | $(5,004,853) |
| Operating Expenses | $1,301,090 | $2,770,372 | $5,011,394 |
| Cash and Equivalents (End of Period) | $1,808,574 | $1,808,574 | $6,400,732 |
| Working Capital | $1,276,246 | $1,276,246 | N/A |
| Accumulated Deficit | $(105,700,341) | $(105,700,341) | $(96,935,005) |
| Warrant Liability | $328,610 | $328,610 | $799,284 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 45% year-over-year for the six-month period (from $5.01M to $2.77M). This was driven by significant reductions in Research & Development (down 48%) and General & Administrative expenses (down 40%), attributed to restructuring and a shift in focus toward clinical trials and commercialization.
- Net Loss Improvement: The net loss for the six months ended June 30, 2025, was $2.26M, a significant improvement compared to the $5.00M loss in the same period in 2024. This improvement was aided by a $470,674 gain from the change in fair value of warrant liabilities.
- Cash Position: Cash reserves declined from $3.23M at year-end 2024 to $1.81M at June 30, 2025, reflecting a net cash burn of $2.41M from operating activities.
- Capital Structure: The company issued 215,482 shares of common stock under its At-The-Market (ATM) program, raising net proceeds of approximately $1.0M.
Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. Management notes that existing cash is insufficient to fund operations for the next 12 months without additional financing.
- Cryptocurrency Strategy: In July 2025, the Board authorized a cryptocurrency treasury strategy, engaging Anchorage Digital Bank as a custodian and Arca Investment Management to manage holdings. As of the filing date, no cryptocurrency has been acquired.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, citing a material weakness due to insufficient personnel resources to segregate duties in the accounting function.
- Regulatory Path: The company continues to pursue FDA approval for its NAFLD TAEUS application. No revenue is expected until regulatory approvals are secured and commercialization begins.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for securing additional capital given the $1.8M cash balance and $2.4M operating cash burn over six months.
- Cryptocurrency Implementation: Monitor subsequent filings for actual acquisition of digital assets and the impact on the balance sheet and volatility.
- Remediation of Controls: Track progress on hiring accounting personnel to address the material weakness in internal controls over financial reporting.
- ATM Program Utilization: Review the remaining capacity under the $6.2M ATM agreement and the pricing of recent share issuances.
- Regulatory Milestones: Confirm the status of the de novo application with the FDA for the NAFLD TAEUS system.